Brief: First Patient Dosed In Ongoing Rainier Trial Achieved 90% Reduction In Leukemic Blasts Within The First 30 Days Of Treatment
20/11/2024 13:43
Nov 20 (Reuters) - Aptevo Therapeutics Inc APVO.O :
* APTEVO THERAPEUTICS - FIRST PATIENT DOSED IN ONGOING
RAINIER
TRIAL ACHIEVED 90% REDUCTION IN LEUKEMIC BLASTS WITHIN THE FIRST
30 DAYS OF TREATMENT
* APTEVO THERAPEUTICS - FAVORABLE EARLY SAFETY, EFFICACY,
TOLERABILITY,DURABILITY OF REMISSION DATA INFORMED CO'S ONGOING
RAINIER PHASE 1B/2 TRIAL
Source text: ID:
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary